ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
9 announcements with these filters
An immediate relative of a Divis Laboratories promoter bought equity shares worth ₹0.58 Crore through a market purchase.
Designated Person PRASAD Y.T.S. disclosed the release of two share pledges involving 2,734 equity shares. The combined transaction value of the released pledges is Rs. 2.56 Crore.
Designated person PRASAD Y.T.S. sold 6,234 equity shares of Divis Laboratories Ltd for ₹5.84 Crore via market sale.
K. Sridevi, an immediate relative, sold 200 equity shares of Divi's Laboratories Ltd via a market sale worth ₹0.19 Crore.
K. Sridevi, an immediate relative, sold 200 equity shares of Divi's Laboratories Ltd in a market transaction valued at ₹18.56 Lakh.
Divi's Laboratories showcases dominant market positioning in APIs and custom synthesis with ~$1.25B revenue, focusing on volume-led growth across 100+ countries.
Divi's Laboratories Ltd reported revenue from operations of ₹3,080 Cr (+27.8% YoY) and net profit of ₹902 Cr (+65.5% YoY) for Q1 FY27.
Divis reported FY26 revenue of ₹11,067 cr (up 14%) and PAT of ₹2,568 cr. Management focuses on expanding custom synthesis and peptide capabilities while navigating geopolitical logistics challenges.
Divi's Laboratories Ltd reported revenue from operations of ₹2,831 Cr (+9.5% YoY) and net profit of ₹751 Cr (+13.4% YoY) for Q4 FY26.